Published on 2 May 2024 on Zacks via Yahoo Finance
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
Corcept Therapeutics Incorporated CORT reported first-quarter 2024 earnings of 25 cents per share, which beat the Zacks Consensus Estimate of 21 cents. The company had reported earnings of 14 cents per share in the year-ago quarter.
Revenues increased 39% year over year to $146.8 million. The figure beat the Zacks Consensus Estimate of $138 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.
Quarter in Detail